Gilead Sciences, Inc. (GILD)

Quick facts

Marketed products

• Biktarvy · Immunology · revenue 13400
  Biktarvy works by binding to the integrase enzyme, preventing the HIV virus from integrating its genetic material into the host cell's DNA.
• Vemlidy · Immunology · revenue 2800
  Vemlidy works by inhibiting the HIV reverse transcriptase enzyme, preventing viral replication.
• Emtriva · Immunology · revenue 2400
  Emtriva works by blocking the reverse transcriptase enzyme, which is necessary for HIV to replicate.
• Veklury · Metabolic · revenue 2200
  Remdesivir is an antiviral nucleotide analog RNA polymerase inhibitor with activity against SARS-CoV-2.
• Sunlenca · Infectious Disease · revenue 1600
  Sunlenca works by binding to a specific site on the HIV-1 protease, preventing the virus from replicating.
• Livdelzi · Metabolic · revenue 200
  Livdelzi works by inhibiting the activity of a specific enzyme involved in the progression of liver disease.
• Hepsera · Infectious Disease
  Hepsera works by mimicking a building block of DNA, which it uses to trick the Hepatitis B Virus into incorporating faulty genetic material, ultimately halting its replication.
• Letairis · Cardiovascular
• Vistide · Immunology
• CILO
• Tybost · Oncology
  Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications.
• COPE
• Current HAART regimen
• EFV+3TC+TDF · Infectious Disease
• EFV+TDF · Infectious Disease
• Vitekta · Immunology
  Vitekta blocks the integrase enzyme, preventing HIV from replicating.
• Jyseleca · Immunology
• Harvoni · Other
• Hepsera · Infectious Disease

Phase 2 pipeline

• MBX-8025

Phase 1 pipeline

• GS-0151
• GS-0201
• GS-5745
• GS-7340

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Gilead Sciences, Inc. portfolio CI brief
• Gilead Sciences, Inc. pipeline updates RSS